Miller Lab

What Miller Lab does

Miller Lab is an academic cardiovascular genomics research laboratory within the University of Virginia School of Medicine's Department of Genome Sciences (formerly the Center for Public Health Genomics), founded in 2017 by Principal Investigator Dr. Clint L. Miller. The lab focuses on integrating large-scale human genetics and genomics datasets with clinically relevant functional models to investigate causal mechanisms underlying coronary artery disease and atherosclerosis, with specific emphasis on interpreting non-coding regulatory variation, gene-gene and gene-environment interactions, mural cell biology, and drug repositioning opportunities. It serves the academic research community, and has produced over 100 publications in high-impact journals including Nature Genetics, Cell, European Heart Journal, Circulation Research, and ATVB.

The lab's technical platform combines multi-ancestry genetic analyses, single-cell genomics, spatial transcriptomics, snATAC-seq chromatin accessibility profiling, and integrative multi-omics approaches. It has developed and open-sourced several bioinformatics tools, including PlaqView (a single-cell genomics portal and analysis pipeline for atherosclerosis research), scRNAutils (a single-cell RNA-seq utility package for data processing and visualization), RNA-Seq-Flow (a bulk RNA-Seq snakemake workflow), and MetaPlaq (an in-development integrative single-cell meta-analysis tool for atherosclerosis). The team of approximately 10 personnel includes the PI, a visiting professor from UMC Utrecht, senior research scientists, postdoctoral fellows (including an AstraZeneca-funded fellow), PhD students, MSTP students, a data analyst, and lab specialists.

Miller Lab operates as a non-commercial academic entity funded primarily through NIH grants. Its funding milestones include an NHLBI R00 grant in 2018, an NHLBI R01 grant in 2022, a Chan Zuckerberg Institute Data Insights award in 2022, a $2.8 million NHLBI grant in July 2024 for coronary artery disease research, and a $2.9 million NIH/NIDDK collaborative award in September 2024 for atherosclerosis in diabetes research. Outputs are disseminated through peer-reviewed publications, conference presentations (ASHG, AHA Scientific Sessions, Vascular Discovery, Karolinska symposiums), open-source software on GitHub, and strategic collaborations with UMC Utrecht, Karolinska Institute, Stanford, Mount Sinai, the NHLBI-funded TOPMed Program, the Fondation Leducq Plaqomics Transatlantic Network, and the NIH CaRe-T1D Consortia.

Name

Miller Lab

Legal name

Miller Lab

Website

https://millerlab.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Miller Lab is an academic cardiovascular genomics research laboratory at the University of Virginia's Department of Genome Sciences, founded in 2017. It integrates large-scale human genetics with functional genomics to investigate coronary artery disease and atherosclerosis mechanisms, employing approximately 10 researchers and releasing open-source bioinformatics tools for the global research community.

Ownership category

akta.pro rank

Product category

Cardiovascular Genomics Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

akta.pro secondary industry

Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Cardiovascular genomics research
• Single-cell analysis
• Bioinformatics software tools
• Atherosclerosis research
• Multi-omics analysis

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Research Funding: Funded by NIH/NHLBI, NIH/NIDDK grants and other research funding to conduct cardiovascular genomics research
2. Government Grants: $2.8 million NHLB grant for coronary artery disease research; $2.9 million NIH/NIDDK collaborative award for atherosclerosis in diabetes research

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Miller Lab is an academic research laboratory at the University of Virginia School of Medicine that conducts cardiovascular genomics research, integrating large-scale human genetics and genomics datasets with functional models to investigate causal mechanisms of coronary artery disease and atherosclerosis. The lab develops and releases open-source bioinformatics tools (PlaqView, scRNAutils, RNA-Seq-Flow) and publishes findings in high-impact journals for the broader research community.

Product overview

Miller Lab operates as an academic research laboratory rather than a commercial product company. The lab develops and releases open-source bioinformatics tools and software packages for cardiovascular genomics research. The core offerings include PlaqView (an open-source single-cell genomics portal for cardiovascular research), RNA-Seq-Flow (a bulk RNA-Seq analysis pipeline using Snakemake workflows), and scRNAutils (a single-cell RNA-seq utility package for data processing and visualization). These tools are made publicly available through the Miller Lab GitHub organization (github.com/MillerLab-CPHG) and are intended for research use by the scientific community studying atherosclerosis and cardiovascular diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• PlaqView Open-source single-cell genomics portal and analysis pipeline for cardiovascular research, enabling exploration and visualization of atherosclerosis-related single-cell data.
• RNA-Seq-Flow Bulk RNA-Seq analysis pipeline built using Snakemake workflows for processing and analyzing RNA sequencing data in research settings.
• scRNAutils Single cell RNA-seq package of utilities for streamlined data processing, quality control, and visualization of single-cell genomics data.
• MetaPlaq Integrative Single-Cell Meta-Analysis tool for atherosclerosis research, developed with Chan Zuckerberg Institute Data Insights award to enable large-scale meta-analyses of single-cell data.

Quantifiable outcome

• Multi-ancestry genome-wide analysis identified effector genes and druggable pathways for coronary artery calcification published in Nature Genetics
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• University Medical Center Utrecht (UMC Utrecht)coreStrategic or Co-development Partner · 13 August 2023Dr. Sander W. van der Laan serves as Visiting Professor at UVA Miller Lab. Collaborative research focused on genetic and epigenetic causes of carotid and coronary atherosclerosis underlying ischemic stroke and coronary artery disease.
• Karolinska InstitutecoreStrategic or Co-development PartnerDr. Miller and Dr. van der Laan presented at Karolinska Institute symposium on single-cell and functional genomics of atherosclerosis. Collaborative research on vascular disease mechanisms.
• TOPMed Program (Trans-Omics for Precision Medicine)flagshipStrategic or Co-development PartnerMiller Lab joined the NHLBI funded TOPMed Program, participating in multi-omics precision medicine research for cardiovascular disease.
• Fondation Leducq (Plaqomics)flagshipStrategic or Co-development PartnerTransatlantic Network of Excellence awarded to investigate atherosclerosis (Plaqomics) with January 2019 start date.
• NIH CaRe-T1D ConsortiacoreStrategic or Co-development PartnerCollaborative research on cardiovascular complications of Type 1 Diabetes, presenting at annual scientific meetings.
• Mete Civelek, Suna Onengut-Gumuscu, Sander W. van der LaancoreStrategic or Co-development PartnerNIH/NIDDK funded collaborative network to identify molecular drivers of atherosclerosis in diabetes using multi-omic single-cell and spatial approaches.
• Ron Do (Icahn School of Medicine at Mount Sinai)coreStrategic or Co-development PartnerCollaboration on rare variant contribution to heritability of coronary artery disease published in Nature Communications.
• Chan Zuckerberg InstituteflagshipStrategic or Co-development PartnerData Insights award to develop MetaPlaq - Integrative Single-Cell Meta-Analysis for Atherosclerosis.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Regeneron Genetics Center: Large-scale human genetics research center within Regeneron performing genomic sequencing and phenotypic analysis to identify drug targets. Directly comparable to Miller Lab in integrating large-scale human genetics with functional validation, though operating at much larger industry scale.
• UK Biobank: Large-scale biomedical database and research resource containing genetic, lifestyle, and health information from 500,000+ UK participants. Comparable in enabling large-scale human genetics research that Miller Lab leverages through consortia.
• deCODE genetics (Amgen): Population genomics company based in Iceland (Amgen-owned) conducting large-scale human genetics studies to identify disease variants and drug targets. Comparable in human genetics approach for disease mechanism discovery, particularly for cardiovascular and metabolic conditions.
• AstraZeneca Cardiovascular R&D: Industry partner funding a postdoctoral fellow at Miller Lab (Maria Murach) and conducting cardiovascular drug discovery. Comparable focus on cardiovascular disease mechanisms and therapeutic translation, with substantially larger industry resources.

Others

• Human Cell Atlas: International consortium creating comprehensive reference maps of all human cells using single-cell genomics. Miller Lab's PlaqView and MetaPlaq tools contribute directly to the cardiovascular and atherosclerosis cell atlas efforts within this initiative.
• TOPMed Program (NHLBI): NHLBI-funded Trans-Omics for Precision Medicine program in which Miller Lab participates, generating multi-omics data on large populations for cardiovascular and other disease research.

Direct peers

• Björkegren Lab (Karolinska Institute): Cardiovascular genomics research group at Karolinska studying integrative network and single-cell genomics of atherosclerosis. Comparable methodology and disease focus; active collaborator with Miller Lab.
• 23andMe Therapeutics: Consumer genetics company with therapeutics division using large-scale human genetic data to identify and validate drug targets. Comparable in the strategy of leveraging human genetics for target discovery and drug repositioning.
• Khera Lab (Broad Institute / Massachusetts General Hospital): Cardiovascular genomics research group led by Dr. Amit Khera focused on polygenic risk scores and human genetics for cardiovascular disease. Highly comparable in using human genetics for cardiovascular disease insight and therapeutic target identification.
• Mete Civelek Lab (University of Virginia): Adjacent cardiovascular genomics research lab at UVA led by Mete Civelek, a co-PI on the NIH/NIDDK atherosclerosis in diabetes project. Directly comparable research methodology (multi-omics, atherosclerosis) and institutional context.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/clintomics
• GitHubgithub.com/MillerLab-CPHG
• LinkedInlinkedin.com/company/miller-lab

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Miller Lab